Thelansis

  An autoimmune encephalitis is a group of conditions involving brain inflammation. The condition encompasses several variants, such as acute disseminated encephalomyelitis, anti-NMDAR receptor encephalitis, Hashimoto’s encephalopathy, LG11/CASPR2-antibody encephalitis, Limbic encephalitis, Rasmussen’s encephalitis. Individuals with Autoimmune encephalitis may have various neurologic and psychiatric symptoms. In most cases, the cause of autoimmune encephalitis is unknown. Diagnosis may include a spinal tap, blood test or MRI. Females are more often affected compared to males. First-line therapy consists of intravenous, high-dose corticosteroid and IVIG/plasmapheresis. In the USA, autoimmune encephalitis is estimated to be 1.2 cases per 100,000 annually.   Thelansis’s “Autoimmune Encephalitis (AIE) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription sha...

 Autoimmune Encephalitis (AIE) is an immune-mediated demyelinating disorder that affects the central nervous system by causing inflammation and damage to the optic nerve, spinal cord, brain, and/or brainstem. The MOG protein is found in the nerve coverings of the central nervous system and is involved in myelin maturation and cell surface interactions. The exact cause of MOGAD is unknown, and it affects males and females equally but is more prevalent in children than adults. The symptoms of MOGAD are categorized into optic neuritis, transverse myelitis, acute disseminated encephalomyelitis (ADEM), and cerebral encephalitis. Diagnosing MOGAD requires a blood test to screen for antibodies and MRI and lumbar puncture. ·        In the USA, the estimated incidence of MOGAD is 1 to 2 per 100,000 individuals annually. Thelansis’s “Autoimmune Encephalitis (AIE) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032" ...

 An autoimmune encephalitis is a group of conditions involving brain inflammation. The condition encompasses several variants, such as acute disseminated encephalomyelitis, anti-NMDAR receptor encephalitis, Hashimoto’s encephalopathy, LG11/CASPR2-antibody encephalitis, Limbic encephalitis, Rasmussen’s encephalitis. Individuals with Autoimmune encephalitis may have various neurologic and psychiatric symptoms. In most cases, the cause of autoimmune encephalitis is unknown. Diagnosis may include a spinal tap, blood test or MRI. Females are more often affected compared to males. First-line therapy consists of intravenous, high-dose corticosteroid and IVIG/plasmapheresis. ·        In the USA, autoimmune encephalitis is estimated to be 1.2 cases per 100,000 annually. Thelansis’s “Autoimmune Encephalitis (AIE) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032" covers disease overview, epidemiology, drug utiliza...